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STEM CELL TRANSPLANTATION IN A PATIENT
WITH LATE-ONSET NEMALINE MYOPATHY AND
GAMMOPATHY
Rod bodies accumulation is the hallmark of several ge-
netically determined congenital myopathies, generally
of neonatal or childhood onset.1 Adult forms are known
as sporadic late-onset nemaline myopathies (SLONM).
Since 1966, 71 patients with SLONM have been de-
scribed.2 Among them, 11 were infected by HIV1,3 and
12 had monoclonal gammopathy,2,4 suggesting that the
association of SLONM with HIV infection or gam-
mopathy may not be fortuitous. Plasmacytic dyscrasia
with monoclonal gammopathy of undetermined signif-
icance (MGUS) can be associated with severe neuro-
muscular disorders, as in POEMS syndrome or AL
amyloidosis, and high-dose chemotherapy with autolo-
gous stem cell transplantation has shown some efficacy
in both situations.5,6 Because of the severity and quick
progression of the gammopathy-associated SLONM,
we decided to propose autologous stem cell transplanta-
tion to the patient presented here.
Case report. In March 2003, a 63-year-old woman,
with no family history of myopathy, presented with
progressive proximal limb-girdle muscle weakness
and myalgia. In February 2005, she was wheelchair-
bound, could neither stand nor walk unaided, and
was totally dependent for many daily life activities
(table; video on the Neurology® Web site at www.
neurology.org). Weakness was particularly severe in
the proximal and axial muscles. She could swallow
and breathe normally, eye and tongue movements
were normal, and her speech was clear. No fascicula-
tions were seen, and tendon reflexes and sensory per-
ception were preserved. Three months later, she was
unable to get out of bed.
Serum creatine kinase activity was 160 U/L (normal
170 U/L). Electromyography showed a non-
neurogenic, myopathic pattern (short duration, small
amplitude, polyphasic motor unit potentials). Muscular
CT scan showed bilateral and symmetric atrophy of the
posterior thigh muscles and of the gastrocnemii.
A monoclonal IgG lambda was detected by serum
immunofixation (integrated peak was 2 g/L, free
light chain kappa/lambda ratio was 0.11 [normal
range 0.26–1.60]). Neither osteolytic nor mass le-
sions were found on CT or MRI of the cranium,
long bones, pelvis, and spine. Bone marrow biopsy
showed normal trilineage maturation with 4% of
plasma cells. Tests for anti-HIV antibodies, anti-
hepatitis C virus antibodies, antiacetylcholine recep-
tor, and antinuclear antibodies were negative.
In a deltoid muscle biopsy specimen, some fibers
were atrophic, scattered, and angulated, containing
reddish granules on Gomori trichrome staining (fig-
ure e-1A). The distribution of type 1 and type 2 fi-
bers was normal. No histiocytic or lymphocytic
infiltration was seen, and there were no necrotizing
fibers nor amyloid deposits. Direct immunostaining
for HLA class I antigens was negative. Electron mi-
croscopy confirmed presence of rods in atrophic fi-
bers (figure e-1B).
In April 2005, the patient received high-dose mel-
phalan (140 mg/m2) followed by autologous periph-
eral stem cell transplantation. Peripheral stem cells
were collected at steady-state after mobilization with
granulocyte colony-stimulating factor (G-CSF)
alone. The only adverse effect of the procedure was
transient hair loss.
She was then seen every 3 to 6 months until May
2007, for a total of 24months. The gammopathy disap-
peared at the first post-transplant visit and has not reap-
peared. Her muscle strength improved steadily (table,
video). At month 24, she could walk easily without the
help of a cane (table, video). A second biopsy performed
at that time in the contralateral deltoid did not show
any rod (data not shown).
Discussion. The prognosis of gammopathy-
associated SLONM seems poor, since out of seven
patients only one remained stable during 4.5 years,
one worsened during his 14 months of follow-up,
and the five remaining ones died within the 5 years
after symptom onset.2 The patient reported here had
a rapidly progressive form of the disease, which justi-
fied our attempt to treat her with an autologous stem
cell transplantation, leading to an improvement in
muscle strength.
Pathophysiology of SLONM is not known, but
the favorable clinical response and the lack of further
observation of the rods after the graft suggest that the
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plasma cell dyscrasia may play a part in triggering the
disease. In amyloidosis there is a clear relationship
between monoclonal gammopathy and AL deposits.
In POEMS syndrome, the plasma cell dyscrasia has a
pathogenetic role, but no clear relationship has been
found between the gammopathy and the clinical
manifestations, which rather appear to be due to high
VEGF levels. However, both these entities improve
when the plasma cell dyscrasia and the monoclonal
component are eradicated.5,6
The risk of death from autologous stem cell trans-
plantation, evaluated at 3% to 5% in multiple my-
eloma,7 seems to be counterbalanced by its efficacy
and by the poor prognosis of gammopathy-associated
SLONM. Nevertheless, in AL amyloidosis, melpha-
lan plus high dose dexamethasone was as effective
and much safer than melphalan plus bone marrow
transplantation.6 These two attitudes will have to be
further evaluated in SLONM.
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SPORADIC LATE-ONSET NEMALINE MYOPATHY
EFFECTIVELY TREATED BY MELPHALAN AND
STEMCELLTRANSPLANT
Sporadic late-onset nemaline myopathy (SLONM) is a
rare, late-onset myopathy that progresses subacutely.
Limb-girdle weakness and atrophy predominate the
clinical picture.1 SLONM is sporadically associated
with a monoclonal gammopathy, which portends an
unfavorable outcome.1-6 We report the successful treat-
ment of a patient with SLONM and monoclonal gam-
mopathy with melphalan and autologous stem cell
transplantation.
Clinical case. In October 2004, a 38-year-old man
with no family history of myopathy started feeling fa-
Table Outcome of muscle functions
Month2 Month 0 Month 3 Month 6 Month 12 Month 18 Month 24
Myalgia    0 0 0 0
Arm abduction 45° 30° 45° 60° ND 120° 160°
Head drop Yes Yes Yes Yes No No No
Legs held outstretched at
45 deg supine
22 s Impossible 60 s 75 s 75 s 75 s 75 s
Gait/time necessary to walk
10meters alone
With help of
someone/ND
Impossible/ND With help of
someone/ND
With 2
canes/18 s
With one
cane/ND
With one
cane/13 s
Alone/11 s
Standing up alone
from a chair
(no. of times in 1min)
Impossible Impossible 1 3 7 10 12
Month 0 date of autologous peripheral stem cell transplantation.
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tigued. In April 2005, he noted weakness of neck exten-
sors, followed by weakness and atrophy of his arms and
shoulders. Impairment of speech and swallowing gradu-
ally developed. In January 2006, he had mild exertional
dyspnea. Laboratory investigations revealed normal
CK, absence of anti-AChR antibodies, and negative vi-
ral serology, including HIV. MRI of the cervical spine
was normal. Electromyography showed small, polypha-
sic units, with moderate spontaneous activity. Right
quadriceps muscle biopsy showed atrophic fibers, but
no signs of inflammation. An M-protein IgG kappa
spike of 7.4 g/L was identified on serum electrophoresis
and was confirmed by immunofixation. Conventional
X-ray of the skeleton revealed no lytic lesions. Results of
bone marrow biopsy showed an increase of monoclonal
plasma cells (10–20%, almost exclusively light chain
kappa positive cells), without signs of amyloidosis.
Hence, monoclonal gammopathy of undetermined sig-
nificance was diagnosed. The neuromuscular differen-
tial diagnosis included motor neuron disorder and
inflammatory myopathy. The patient was treated with
prednisone 70 mg/day for 1 month; however, dysar-
thria, dysphagia, and muscle weakness increased (shoul-
der abduction MRC2; neck extension MRC3; elbow
flexion and extension MRC4) (figure).
Revision of themuscle biopsy showed not only small
groups of angulated or flattened atrophic fibers, but also
scattered fibers with internal nuclei, basophilic areas, or
irregular ATP-ase staining and several lobulated fibers.
On trichrome staining many atrophic fibers were com-
pletely filled with nemaline rods, but also larger fibers
showed central or subsarcolemmal accumulations of
rods, sometimes accompanied by small vacuoles. Both
immunohistochemical staining with alfa-actinin anti-
bodies (figure) and electron microscopy confirmed the
abundance of these rods, classically composed of
Z-band material. No amyloid was detected. Staining
with kappa, lambda, and IgG antibodies revealed no
abnormalities. Mutation analysis of the NEB, TMP3,
and ACTA1 genes was normal. SLONM associated
with monoclonal gammopathy was diagnosed.
Treatment with prednisone had reduced the pres-
ence of the M-protein in serum. To further eradicate
the plasma cell clone in the bone marrow, experi-
mental treatment with one cycle of melphalan (70
mg/m2) with peripheral stem cell collection was per-
formed in March 2006. In May 2006 a course of
high dose melphalan with autologous stem cell trans-
plantation was performed. Two months later no
M-protein was detectable in the serum, and on bone
marrow examination no monoclonal plasma cells
were detected. The patient attended a rehabilitation
program. 15-Month clinical follow-up showed ap-
parent improvement of muscle force and mass
(shoulder abduction MRC3; neck extension MRC4;
elbow flexion MRC4; elbow extension MRC5).
Functional improvement was also impressive: he was
able to walk upstairs and run again, speaking and
swallowing were normal, and he had started working
again. Cardiac and pulmonary screening were then
Figure Clinical and histological features of
patient with sporadic late-onset
nemaline myopathy associated with
monoclonal gammopathy
(A) Physical examination in February 2007 revealed dys-
arthria, dysphagia, atrophy of temporal and frontal mus-
cles, severe muscle weakness, and atrophy of upper and
lower arms and axial muscles. Maximal anteflexion with
compensatory neck flexion (left); maximal abduction
(right). Fasciculations were absent and deep tendon re-
flexes of arms were low. (B) Quadriceps muscle biopsy
revealed variation of muscle fiber diameter, with scat-
tered atrophic fibers, some of which are quite basophilic
(hematoxylin-eosin; bar  100 m). (C) Muscle fiber filled
with rods (electron microscopy of frozen tissue; mark on
bar  2 m).
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normal. Right quadriceps muscle biopsies in August
2006 and August 2007 showed scattered atrophic,
lobulated fibers. Nemaline rods were observed nei-
ther in the Gomori trichrome staining nor on elec-
tron microscopy.
Discussion. SLONM is an atypical disorder that
normally presents after age 40 and progresses sub-
acutely. Limb-girdle weakness and atrophy predomi-
nate the clinical picture, but distal weakness, head
drop, respiratory insufficiency, and dysphagia can
also occur.1 Although fasciculations and hyperre-
flexia are absent, patients may be misdiagnosed with
motor neuron disease. Recognition of nemaline rods
on trichrome staining is crucial. This can be con-
firmed by immunohistochemical staining with alfa-
actinin antibodies of the muscle biopsy.
Presence of monoclonal gammopathy in SLONM
portends an unfavorable outcome: the majority of these
patients die within 1 to 5 years of respiratory failure,
despite immunosuppressive treatment.1 Presence of a
monoclonal protein at the sarcolemma and responsive-
ness to immunosuppressive treatment are suggestive of
an autoimmune origin.1,4,5 In contrast to these previ-
ously reported cases, this patient showed significant im-
provement of muscle strength and function that was
accompanied by a remarkable improvement of the
muscle histology in response to treatment. Treatment
with high dose melphalan and stem cell transplantation
has a relatively low mortality when cardiac or visceral
involvement is absent.7 Since the natural course of
SLONMwith monoclonal gammopathy is devastating,
this report is imperative and calls for further study. Fi-
nally, it stresses the importance of recognition of this
remarkable mimic of motor neuron disease.
e-Pub ahead of print on June 18, 2008, at www.neurology.org.
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